Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 5860657, 7 pages
http://dx.doi.org/10.1155/2016/5860657
Research Article

Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly

Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. and A. Seràgnoli”, University of Bologna, Bologna, Italy

Received 13 April 2016; Accepted 17 August 2016

Academic Editor: Tomoki Nakamura

Copyright © 2016 Daria Sollazzo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Kleppe and R. L. Levine, “New pieces of a puzzle: the current biological picture of MPN,” Biochimica et Biophysica Acta—Reviews on Cancer, vol. 1826, no. 2, pp. 415–422, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Cazzola and R. Kralovics, “From Janus kinase 2 m Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloprolife,” Blood, vol. 123, no. 24, pp. 3714–3719, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Tefferi and A. Pardanani, “Myeloproliferative neoplasms: a contemporary review,” JAMA Oncology, vol. 1, no. 1, pp. 97–105, 2015. View at Publisher · View at Google Scholar
  4. T. Klampfl, H. Gisslinger, A. S. Harutyunyan et al., “Somatic mutations of calreticulin in myeloproliferative neoplasms,” The New England Journal of Medicine, vol. 369, no. 25, pp. 2379–2390, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Nangalia, C. E. Massie, E. J. Baxter et al., “Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2,” New England Journal of Medicine, vol. 369, no. 25, pp. 2391–2405, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Rampal, F. Al-Shahrour, O. Abdel-Wahab et al., “Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis,” Blood, vol. 123, no. 22, pp. e123–e133, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. H. C. Hasselbalch, “The role of cytokines in the initiation and progression of myelofibrosis,” Cytokine and Growth Factor Reviews, vol. 24, no. 2, pp. 133–145, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. A. G. Fleischman, “Inflammation as a driver of clonal evolution in myeloproliferative neoplasm,” Mediators of Inflammation, vol. 2015, Article ID 606819, 6 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. H. L. Geyer, A. C. Dueck, R. M. Scherber, and R. A. Mesa, “Impact of inflammation on myeloproliferative neoplasm symptom development,” Mediators of Inflammation, vol. 2015, Article ID 284706, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. H. C. Hasselbalch and M. E. Bjørn, “MPNs as inflammatory diseases: the evidence, consequences, and perspectives,” Mediators of Inflammation, vol. 2015, Article ID 102476, 16 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Hermouet, E. Bigot-Corbel, and B. Gardie, “Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation,” Mediators of Inflammation, vol. 2015, Article ID 145293, 16 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Tefferi, R. Vaidya, D. Caramazza, C. Finke, T. Lasho, and A. Pardanani, “Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study,” Journal of Clinical Oncology, vol. 29, no. 10, pp. 1356–1363, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. W.-A. Wang, J. Groenendyk, and M. Michalak, “Calreticulin signaling in health and disease,” International Journal of Biochemistry and Cell Biology, vol. 44, no. 6, pp. 842–846, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. E. Pike, L. Yao, J. Setsuda et al., “Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth,” Blood, vol. 94, no. 7, pp. 2461–2468, 1999. View at Google Scholar · View at Scopus
  15. W.-F. Cheng, C.-F. Hung, C.-Y. Chai et al., “Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen,” The Journal of Clinical Investigation, vol. 108, no. 5, pp. 669–678, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Gold, D. Williams, J. Groenendyk, M. Michalak, and P. Eggleton, “Unfolding the complexities of ER chaperones in health and disease: report on the 11th international calreticulin workshop,” Cell Stress and Chaperones, vol. 20, no. 6, pp. 875–883, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. Y.-C. Lu, W.-C. Weng, and H. Lee, “Functional roles of calreticulin in cancer biology,” BioMed Research International, vol. 2015, Article ID 526524, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Eggleton, E. Bremer, E. Dudek, and M. Michalak, “Calreticulin, a therapeutic target?” Expert Opinion on Therapeutic Targets, vol. 20, no. 9, pp. 1137–1147, 2016. View at Publisher · View at Google Scholar
  19. I. Chachoua, C. Pecquet, M. El-Khoury et al., “Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants,” Blood, vol. 127, no. 10, pp. 1325–1335, 2016. View at Publisher · View at Google Scholar
  20. M. Araki, Y. Yang, N. Masubuchi et al., “Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms,” Blood, vol. 127, no. 10, pp. 1307–1316, 2016. View at Publisher · View at Google Scholar
  21. J. W. Vardiman, J. Thiele, D. A. Arber et al., “The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes,” Blood, vol. 114, no. 5, pp. 937–951, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Palandri, R. Latagliata, N. Polverelli et al., “Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis,” Leukemia, vol. 29, no. 6, pp. 1344–1349, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. “ISCN 1995,” in Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature, F. Mitelman, Ed., S Karger, Basel, Switzerland, 1995.
  24. F. Passamonti, F. Cervantes, A. M. Vannucchi et al., “A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment),” Blood, vol. 115, no. 9, pp. 1703–1708, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. A. M. Vannucchi, G. Rotunno, N. Bartalucci et al., “Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value,” Leukemia, vol. 28, no. 9, pp. 1811–1818, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. K. E. Panteli, E. C. Hatzimichael, P. K. Bouranta et al., “Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases,” British Journal of Haematology, vol. 130, no. 5, pp. 709–715, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. C.-C. Duo, F.-Y. Gong, X.-Y. He et al., “Soluble calreticulin induces tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 production by macrophages through mitogen-activated protein kinase (MAPK) and NFκB signaling pathways,” International Journal of Molecular Sciences, vol. 15, no. 2, pp. 2916–2928, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. M. R. Garbati, C. A. Welgan, S. H. Landefeld et al., “Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism,” American Journal of Hematology, vol. 91, no. 2, pp. 211–219, 2016. View at Publisher · View at Google Scholar
  29. S. Vig, A. K. Pandey, G. Verma, and M. Datta, “C/EBPα mediates the transcriptional suppression of human calreticulin gene expression by TNFα,” The International Journal of Biochemistry & Cell Biology, vol. 44, no. 1, pp. 113–122, 2012. View at Publisher · View at Google Scholar · View at Scopus